Literature DB >> 10433568

Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy.

L A Clough1, E D'Agata, S Raffanti, D W Haas.   

Abstract

Many patients infected with human immunodeficiency virus type 1 (HIV-1) have suboptimal responses to protease inhibitor-based therapy. We retrospectively evaluated a cohort of 104 HIV-positive adults, most of whom had previously received antiretrovirals, to identify the frequency and clinical predictors of incomplete response to potent HIV-1 protease inhibitors. Sixty-two (60%) of the patients had an incomplete response, defined as a plasma HIV-1 RNA level of >400 copies/mL after 20 weeks of therapy. Logistic regression analysis identified the following independent risk factors for incomplete response: elevated baseline plasma HIV-1 RNA level (P = .03), low baseline weight (P = .01), chemoprophylaxis for Pneumocystis carinii pneumonia (P = .04), and active illicit drug use (P = .04). Regular prescription of narcotics or benzodiazepine anxiolytics (P = .01) and use of any Internet site (P = .01) predicted a more favorable response. Identifying factors that predict suboptimal response to protease inhibitors improves our understanding of interpatient variability in response to therapy and should foster strategies that enhance the effectiveness of current and future regimens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433568     DOI: 10.1086/520185

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Health care problems in prisons.

Authors:  P M Ford; W L Wobeser
Journal:  CMAJ       Date:  2000-03-07       Impact factor: 8.262

2.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

3.  Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.

Authors:  J M Kilby; G Sfakianos; N Gizzi; P Siemon-Hryczyk; E Ehrensing; C Oo; N Buss; M S Saag
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men.

Authors:  Gregory S Zaric; Ahmed M Bayoumi; Margaret L Brandeau; Douglas K Owens
Journal:  Med Decis Making       Date:  2008-03-18       Impact factor: 2.583

5.  Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.

Authors:  Cara C Wilson; Mark J Newman; Brian D Livingston; Samantha MaWhinney; Jeri E Forster; Jim Scott; Robert T Schooley; Constance A Benson
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

6.  Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.

Authors:  David W Haas; Benjamin Johnson; Janet Nicotera; Vicki L Bailey; Victoria L Harris; Farideh B Bowles; Stephen Raffanti; Jennifer Schranz; Tyler S Finn; Alfred J Saah; Julie Stone
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

7.  How well do clinicians estimate patients' adherence to combination antiretroviral therapy?

Authors:  Loren G Miller; Honghu Liu; Ron D Hays; Carol E Golin; C Keith Beck; Steven M Asch; Yingying Ma; Andrew H Kaplan; Neil S Wenger
Journal:  J Gen Intern Med       Date:  2002-01       Impact factor: 5.128

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.